Scientific and clinical translational research highlighting treatment advances in the field of HCT are available in five review articles in Blood. The introduction, written by Dr. Robert Negrin, summarizes the impact of the research: “Hematopoietic cell transplantation (HCT) has developed from a treatment of last resort into a common medical procedure with the capability of curing complex hematologic malignancies, repairing dysfunctional hematopoietic stem cells, and inducing tolerance to solid organ allografts.” Topics are: HCT donor sources in the 21st century; Conditioning regimens for HCT; Biology of GVHD; Update on acute GVHD; and Current issues in chronic GVHD.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Review Series in Blood Journal: Advances in HCT
Aug 2014